News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pacgen Biopharmaceuticals Corporation Completes Share Consolidation


6/8/2010 9:34:55 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 08, 2010) - Pacgen Biopharmaceuticals Corporation (the "Company" or "Pacgen") (TSX VENTURE: PGA) announced today that it has completed its previously announced consolidation of its common shares (the "Common Shares") on the basis of one post-consolidation Common Share for every two existing Common Shares (the "Consolidation"). The Common Shares of Pacgen will commence trading on the TSX Venture Exchange on the consolidated basis at market's opens today.

The Company also announced that it has obtained regulatory approvals to issue 22,618,143 post-consolidation Common Shares pursuant to its previously announced non-brokered private placement financing (the "Financing") of subscription receipts ("Subscription Receipts") for aggregate subscription proceeds of $600,000, and financial restructuring of up to approximately $1.9 million of indebtedness (the "Financial Restructuring"). The 22,618,143 post-consolidation Common Shares to be issued today include (i) an aggregate of 10,000,001 Common Shares issuable in connection with the automatic exercise, for no additional consideration, of each Subscription Receipt for one post-consolidation Common Share and (ii) an aggregate of 12,618,142 post-consolidation Common Shares issuable in connection with the conversion of an aggregate of approximately $879,000 of indebtedness (the "Shares for Debt Conversion") as part of the Financial Restructuring. All Common Shares issued under the Financing and the Shares for Debt Conversion will be subject to a four month hold period which will end on September 29, 2010 and October 9, 2010, respectively. Following the Consolidation and the completion of these share issuances, the Company will have 41,690,489 of Common Shares issued and outstanding.

The Shares for Debt Conversion includes settlement of approximately $658,000 of past due debentures, approximately $57,000 of trade payables and approximately $164,000 of licensing obligations. The Company expects the remaining balance of the restructured indebtedness and financial commitments to be settled by cash discounts, prepaid amounts or future payments linked to performance milestones.

This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act of 1933 and applicable state securities laws or an exemption from such registration is available.

About Pacgen

Pacgen is a life science technology transfer company focused on the commercial development of novel therapeutic drug candidates up to Phase II, proof of concept efficacy in human. Pacgen sources innovative therapeutic drug candidates globally, and develops these drug candidates in accordance to the United States Food and Drug Administration regulatory standards to feed the product development pipelines of the pharmaceuticals industry. Pacgen's technology portfolio is composed of PAC-113, an anti-fungal for the treatment of oral Candidiasis, and PAC-G31P, a novel peptide therapeutic designed to treat inflammatory diseases characterized by non-beneficial neutrophil.

PAC-113 is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in human saliva. This peptide alters the permeability of fungal cell membranes causing cell death. In June 2008, Pacgen announced positive results from its Phase IIb clinical trial demonstrating that PAC-113 is effective in the treatment of oral Candidiasis and compares favourably to the efficacy demonstrated by Nystatin, a current standard of care. PAC-G31P is a small recombinant protein that is a synthetic analogue of the human cytokine called Interleukin-8 which is the key chemokine involved in neutrophil recruitment. PAC-G31P is currently being investigated in preclinical studies for its potential to treat inflammatory diseases characterized by non-beneficial neutrophil. For additional information, please visit www.pacgenbiopharm.com.

Forward looking Statements

Certain statements included in this press release may be considered forward-looking. Statements relating to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments constitute forward-looking statements. All forward-looking statements are based on Pacgen's current beliefs and expectations as well as assumptions relating to the successful completion of its clinical trials and pre-clinical studies, the time and process required to obtain regulatory approval for commercialization of its product, the ability of Pacgen to raise additional capital in future on favourable terms, the impact of competitive products and pricing in the market, new product development, and the successful and timely completion of corporate collaborations or licensing arrangements for its research programs. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with completion of clinical trials and obtaining regulatory approval, dependence on collaborative partners, and our ability to protect our intellectual property.

Wherever possible, words such as "anticipate", "believe", "expect", "may", "could", "will", "potential", "intend", "estimate", "should", "plan", "predict", "project" or the negative or other variations of such expressions reflect Pacgen's current beliefs and assumptions and are based on the information currently available to Pacgen. Certain risks and uncertainties, including those risk factors identified by Pacgen in its annual management's discussion and analysis dated July 9, 2009 and annual information form dated July 31, 2008, may cause our actual results, level of activity, performance or achievements to differ materially from those implied by forward looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Pacgen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For all forward-looking statements, Pacgen claims the safe harbour for forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.


Contacts:
Pacgen Biopharmaceuticals Corporation
Yiu Chung Lee
Chief Executive Officer
416-805-8573
yclee@pacgenbiopharm.com

Pacgen Biopharmaceuticals Corporation
Christina Yip
Chief Financial Officer
604-436-4388
cyip@pacgenbiopharm.com
www.pacgenbiopharm.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES